Peer-reviewed veterinary case report
Effects of CpG gelatin nanoparticles on blood cells in dogs
By Prélaud, Ana Rostaher et al.·Published in Veterinary dermatology·2013·Vetsuisse Faculty University of Zurich, Germany·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: In vitro effects of CpG oligodeoxynucleotides delivered by gelatin nanoparticles on canine peripheral blood mononuclear cells of atopic and healthy dogs - a pilot study.
- Species:
- dog
Plain-English summary
A group of eight dogs with atopic dermatitis (a skin allergy) were tested with a new treatment involving CpG oligodeoxynucleotides delivered by gelatin nanoparticles to see if it could help their condition. The researchers found that this treatment increased levels of a specific immune response marker (IL-10) after 24 hours, suggesting it might help manage allergies in dogs. While there were no significant changes in other immune markers, the increase in IL-10 indicates potential for this treatment to support dogs with allergies. Further studies are needed to see how this could be applied in real-world situations.
People also search for: dog skin allergy treatment · atopic dermatitis in dogs · CpG treatment for dog allergies
Abstract
BACKGROUND: Cytosine-phosphate-guanine (CpG) oligodeoxynucleotides offer a novel promising immunotherapeutic approach for atopic dermatitis (AD) both in humans and animals. Gelatin nanoparticles (GNP) enhance and prolong CpG-associated immunomodulatory effects and minimize adverse effects both in vitro and in vivo. Information about the effects of this combination in dogs is lacking. HYPOTHESIS/OBJECTIVES: The aim of this study was to evaluate immunological effects of CpG coupled to GNP on canine peripheral blood mononuclear cells (PBMCs) in vitro. ANIMALS: Eight dogs with AD, diagnosed by standard criteria and with a concurrent immediate hypersensitivity to house dust mites were included. Control samples were taken from eight healthy, age-matched control dogs without history or evidence of cutaneous or systemic illness. METHODS: Peripheral blood mononuclear cells of healthy and allergic dogs were incubated with CpG-GNP and the uptake of CpG-GNP was demonstrated using confocal laser scanning microscopy. Cell culture supernatant concentrations of interferon gamma (IFN-γ), interleukin (IL)-4, IL-6 and IL-10 were measured by Canine Cytokine Milliplex. RESULTS: No significant changes in IFN-γ and IL-4 were found when comparing PBMCs incubated with CpG and CpG-GNP with the negative controls in atopic and healthy dogs. Interleukin-6 was not detected in any of the groups. However, a statistically significant increase in IL-10 concentration was found after 24 h stimulation with CpG-GNP compared with CpG alone both in atopic and healthy dogs. CONCLUSIONS AND CLINICAL IMPORTANCE: As IL-10 is considered an immunosuppressive cytokine playing a key role in peripheral tolerance; the reported CpG-GNP formulation could be a new approach in allergy treatment.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/23826658/